An extension phase II study of the clinical and biologic effects of docetaxel (Taxotere) in patients with locally advanced breast cancer.

Trial Profile

An extension phase II study of the clinical and biologic effects of docetaxel (Taxotere) in patients with locally advanced breast cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2013

At a glance

  • Drugs Docetaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 04 Feb 2013 Status changed from active, no longer recruiting to discontinued as reported by Clinicaltrials.gov.
    • 24 Jan 2012 Planned end date changed from 1 Dec 2013 to 1 Jan 2012 as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Additional lead trial centre and investigator identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top